Skip to content
Menu

Molecular Partners AG MOLN

Full chart Compare
Set alert

Price alert · MOLN

All alert types
2.49 USD -0.17 (-6.57%)

Regular-session close

2.56 +0.07 +2.81%

After hours · Nov 19, 4:10 PM ET

2.67 Day range 2.77
2.63 52-week range 5.36
YTD
-42.89%
1 year
-40.57%

5D -0.04 (-1.38%)

2.702.802.903FriMonTue2.86
Market cap
102.16M
Revenue (ttm)
6.00M
EPS (ttm)
-1.68
Shares out
36.86M
Forward P/E
-2.96
YTD return
-42.89%
1-year return
-40.57%
50-day average
5.63
Volume
93
Avg volume
1.69K
Open
2.77
Previous close
2.67
Day's range
2.67 – 2.77
52-week range
2.63 – 5.36
Beta
0.54
Price target
10.37 (+316.6%)

Key statistics

200-day average
5.30
Enterprise value
27.75M
Price / sales
33.41
Price / book
1.30
Revenue growth
-73.20%
Free cash flow
-38.46M
Total cash
143.62M
Total debt
2.75M
Return on equity
-37.37%
Short % of float
0.21%

Fundamental scorecard

4 of 25 checks passed on MOLN’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
MOLN Revenue — quarterly 0
MOLN Net income — quarterly -11.71M
MOLN EPS — quarterly -0.31

Earnings

MOLN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 31, 2024Sep 1, 2024-0.63-0.57+0.06+9.52%
Aug 26, 2024Jun 1, 20240.00-0.51——
Aug 26, 2024Jun 1, 20240.00———
May 16, 2024Mar 1, 20240.00-0.39——
May 16, 2024Mar 1, 20240.00———
Mar 14, 2024Dec 1, 20230.00———

Upgrades / downgrades

MOLN analyst upgrades and downgrades
DateFirmActionFromTo
Dec 5, 2023JP MorganmainNeutralNeutral
Aug 29, 2022SVB LeerinkdownOutperformMarket Perform
May 25, 2022Credit SuisseupUnderperformNeutral
Apr 27, 2022SVB Leerinkmain—Outperform
Jan 14, 2022SVB Leerinkmain—Outperform
Aug 27, 2021SVB Leerinkmain—Outperform

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland

News

Your note

Sign in to keep a note on MOLN — it syncs with the Stock Master app.

Institution ownership

MOLN institution ownership
Holder% heldSharesValueReported
BVF Inc.1.10%443,2212.41MSep 29, 2024
Suvretta Capital Management, LLC0.99%400,0002.18MSep 29, 2024
UBS Group AG0.01%5,24628.54KSep 29, 2024
Rhumbline Advisers0.00%2691.46KSep 29, 2024
Morgan Stanley0.00%5002.72KSep 29, 2024

Fund ownership

MOLN fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.00%1,0705.82KOct 30, 2024